Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Pemigatinib is a targeted therapy designed for adult patients with advanced, met···【more】
Release date：2024-08-15Recommended：283
The core mechanism of Pemigatinib, a class of small molecule kinase blockers spe···【more】
Release date：2024-08-15Recommended：249
Pemigatinib is the world's first targeted therapy for cholangiocarcinoma.Wha···【more】
Release date：2024-08-15Recommended：298
Pemigatinib is a small-molecule kinase inhibitor targeting FGFR1, 2, and 3 by in···【more】
Release date：2024-08-15Recommended：235
Pemigatinibis the world's first targeted therapy for cholangiocarcinoma for ···【more】
Release date：2024-08-15Recommended：241
Pemigatinib is used in adults to treat bile duct cancer that has spread to other···【more】
Release date：2024-08-14Recommended：256
Selpercatinib is a targeted drug for the treatment of RET gene mutations, which ···【more】
Release date：2024-08-14Recommended：234
Venetoclax reduces the viability of cancer cells by highly selectively inhibitin···【more】
Release date：2024-08-14Recommended：192
Venetoclax is a novel BCL-2 inhibitor that induces apoptosis in cancer cells by ···【more】
Release date：2024-08-14Recommended：223
Venetoclax is the world's only approved selective inhibitor of Bcl-2 that ca···【more】
Release date：2024-08-14Recommended：233
Venetoclax restores normal apoptosis of cancer cells by blocking the anti-apopto···【more】
Release date：2024-08-14Recommended：265
Venetoclax is the only approved inhibitor of Bcl-2, which achieves high selectiv···【more】
Release date：2024-08-14Recommended：228
